Pharmacological Ascorbate Formulations Combined with EDTA Enhance Tumor Cell Killing
This is a new methodof improving the treatment of NSCLC and other cancers. It involvesadministering a novel combination of ascorbate and a metal chelating agent,such as ethylene diamine tetraacetic acid (EDTA), to increase tumor cellssensitivity to common cancer treatment options. When this combination isadministered to a patient, tumor cells have a much lower survival rate than whensubjected to traditional chemotherapy and radiation therapy methods. Increasing the efficacy of these methods couldlower the total cost and treatment time as well as improve patient outcome. Thistechnology could also reduce the need for risky surgical procedures by makingless invasive treatment options, like chemotherapy, more effective.
美國
